CDMO, Oncolytic Viruses
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
125
NCT06265025
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 20, 2024
Completion: Oct 30, 2028
Loading map...